ArticleAdvanced healthcare materials2026
Triazine-Trione Thermosets with High Processability for Scaffold Applications in Bone Tissue Engineering.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Triazine-Trione Thermosets with High Processability for Scaffold Applications in Bone Tissue Engineering.Advanced healthcare materials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Despite advances in scaffold development, many current biomaterials suffer from limited processability or poor biological performance. To address this, we previously introduced two novel triazine-trione (TATO)-based thermosets, T-ene and T-yne, as candidates for tissue engineering applications. In the present study, we aim to comprehensively evaluate the initial cellular response of bone marrow mesenchymal stem/stromal cells (BMSC) on TATO materials and their osteogenic potential, with a particular focus on their suitability for bone tissue engineering applications. Both T-ene and T-yne demonstrated biocompatibility comparable to polycaprolactone (PCL), as assessed by in vitro cell behavior and the chorioallantoic membrane (CAM) assay. Transcriptomic profiling via RNA sequencing of BMSC cultured on the materials revealed upregulation of mitotic processes in cells on T-ene compared to T-yne and PCL. Expression profiling of 92 osteogenic genes after 14 days in osteogenic media showed distinct gene regulation patterns in BMSC on the TATO materials compared to PCL. However, osteogenic differentiation assays, such as Alkaline Phosphatase activity and Alizarin Red R staining, showed no significant differences among the groups. These results suggest that T-ene and T-yne are promising, formable, and biocompatible candidates for use in bone tissue engineering applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.